JTL Industries commissions new ERW pipe manufacturing
The new line will enable JTL to manufacture pipes in the following specifications: h
- Round pipes: 6 to 20 (168 mm OD to 508 mm OD) h
- Square sections: 130 mm x 130 mm to 400 mm x 400 mm h
- Rectangular sections: 100 mm x 160 mm to 300 mm x 500 mm h
- Thickness range: 4 mm to 16 mm
This facility will add a substantial annual capacity of 3,00,000 MTPA, strengthening JTLs position in the value-added and high-strength steel pipe segments. The new line is scheduled to be fully installed and operational within 12 months.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
14 hours ago
- Hans India
Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India
Cohance Lifesciences Limited ('Cohance' or 'the Company'), a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities. Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the Company to take these high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production. Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26. Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: 'Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.' This investment follows the Company's recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.
The Hindu
a day ago
- The Hindu
Cohance to invest $10 million to expand capabilities of U.S. arm, ₹23 cr. in new facility at Hyderabad
Global contract research, development and manufacturing organisation Cohance Lifesciences on Tuesday said it will invest $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary NJ Bio. In another announcement, Cohance said it will be investing ₹23 crore on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The investment in the U.S. will advance its global expansion in niche technology-led modalities, enhancing ability to support innovators from early development through late-phase clinical supply. The build-out of a cGMP compliant bioconjugation suite at NJ Bio's Princeton, New Jersey facility strengthens the company's capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions, Cohance said. The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter. On the investment on the cGMP Oligonucleotide facility in Hyderabad, Cohance (formerly known as Suven Pharma) said the facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. It will enable the company to take high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Customer engagements are underway, with audits planned in coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence by December. Cohance said the two investments are part of planned capacity expansion programme across high-growth modalities enhancing its ability to serve global innovators from early development to commercial supply.
Business Standard
2 days ago
- Business Standard
Dr Reddy's Lab receives EIR from USFDA for Telangana API facility
Dr. Reddy's Laboratories announced that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility (CTO-5) located in Miryalaguda, Telangana. The USFDA has classified the inspection outcome as "Voluntary Action Indicated" (VAI) and confirmed that the inspection is officially closed. According to an exchange filing dated 24 May 2025, the inspection was conducted between 19 May and 24 May 2025. At the conclusion of the inspection, the USFDA had issued a Form 483 with two observations, which Dr. Reddys stated it would address within the stipulated timeline. Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The companys consolidated net profit rose 1.8% to Rs 1,418.10 crore on 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. The scrip rose 0.61% to Rs 1,219 on the BSE.
